ClinicalTrials.gg
CompletedNCT04457674Updated May 13, 2026

Targeting Sleep Homeostasis to Improve Alcohol Use Disorder Treatment Outcomes (M-STAR Study)

An interventional study of Cognitive Behavioral Therapy for insomnia (CBTi) and Sleep Hygiene Education (SHE) in Insomnia and Alcohol Use Disorder, sponsored by University of Michigan. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by University of Michigan · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Insomnia is common in people who are in treatment for alcohol use disorder. It can impact both sleep quality and daytime functioning, as well as make it harder to treat the underlying alcohol use disorder. This study is looking at two types of therapy to help manage insomnia specifically for people also in treatment for alcohol use disorder.

02

Conditions studied

  • Insomnia
  • Alcohol Use Disorder

Keywords

  • Cognitive Behavioral Therapy
  • Sleep Hygiene
03

In context

Sleep Initiation and Maintenance Disorders

2,722 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 726 are open to participants now.

This study's enrollment of 134 is above the median of 68 across 2,350 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

University of Michigan is the lead sponsor of 1,506 studies on the registry; 192 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 133 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet probable (DSM)-5 criteria for Alcohol Use Disorder with ≤12 months of abstinence
  • Planned enrollment into an abstinence-based treatment program
  • Meet probable DSM-5 criteria for chronic insomnia
  • Access to a video chat-capable device and reliable Wi-Fi network

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of, or high suspicion for, sleep disorders other than insomnia
  • Meet probable criteria for bipolar disorder, psychotic disorder, or post-traumatic stress disorder (PTSD)
  • Terminal or progressive physical illness (e.g., cancer), neurological degenerative disease (e.g., dementia), or presence of an unstable medical condition that is the specific cause of insomnia
  • Self-reported pregnancy or intention to become pregnant during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
134 participants (actual)

Study arms

  • Other
    Cognitive Behavioral Therapy for insomnia (CBTi)

    CBTi is a non-medication therapy that includes cognitive and behavioral treatment components.

    Behavioral: Cognitive Behavioral Therapy for insomnia (CBTi)

  • Other
    Sleep Hygiene Education (SHE)

    SHE is a non-medication therapy that focuses on identifying and changing several behavioral and environmental factors that can interfere with sleep.

    Behavioral: Sleep Hygiene Education (SHE)

Interventions

  • BehavioralCognitive Behavioral Therapy for insomnia (CBTi)

    CBTi consists of six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.

  • BehavioralSleep Hygiene Education (SHE)

    SHE participants receive six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.

06

What researchers measure

Primary outcomes

  1. Score from the insomnia severity index (ISI)

    The ISI is a 7-item self-report assessment of the nature, severity and impact of insomnia. Scores range from 0-28 with higher scores suggesting more clinically significant insomnia.

    Time frame: Immediately post treatment

  2. Percent days abstinent from alcohol as documented in the timeline follow-back (TLFB)

    The Alcohol TLFB is an interviewer-based drinking assessment method to estimate drinking behaviors, including both frequency and quantity of consumption.

    Time frame: Immediately post treatment

Secondary outcomes

  1. Score from Multidimensional Fatigue Inventory (MFI), General Fatigue sub-scale

    The MFI is a 20-item assessment that provides an overall fatigue score (20-100) in addition to 5 separate dimensions of fatigue: general fatigue, physical fatigue, reduced motivation, reduced activity, and mental fatigue. Sub-scale scores range from 4-20 with higher scores indicating higher levels of fatigue.

    Time frame: Immediately post treatment

07

Study locations

1 site
  • The University of Michigan
    Ann Arbor, Michigan 48109, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified data will be shared through the National Institute of Mental Health (NIMH) Data Archive. Only information relevant to the research project will be shared, which may include demographic information such as gender and age, responses to surveys and results found from the research project. Participants identifying data will not be shared in any way and information related to participants will be given a different random identifier known as a Global Unique Identifier or GUID. This number will not coincide with any identifier for data stored on University of Michigan study databases.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: The data will be available following data collection and for 1-2 years following the end of the study grant.

Access criteria: Data shared via the NIMH database is accessible by those associated with NIH institutions who have also signed data sharing agreements.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04457674
Responsible party
J. Todd Arnedt (Associate Professor of Psychiatry, University of Michigan) — Principal investigator
First posted
Jul 7, 2020
Start date
Nov 12, 2020
Primary completion
Mar 31, 2026
Completion
Mar 31, 2026
Last update
May 13, 2026

Study contacts

J Todd Arnedt, Ph.D.
principal investigator · University of Michigan

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion